Two Experimental Drugs Found Effective Against Ebola Virus
International health officials say two experimental drugs used to treat Ebola infections appear to be saving lives in the Democratic Republic of the Congo (DRC).
Dr. Anthony Fauci of the U.S. National Institutes of Health (NIH) called the early results "some very good news." He said the new drugs "...may be able to improve the survival of people with Ebola." The NIH helped support the research.
The findings come from a study of four different drugs that started in November of last year. But an independent monitoring group recommended last week that the study be ended early. The group recommended that all new patients should receive either of the two drugs that showed the best results.
The drugs are antibodies that work by blocking the virus in the body. One drug, REGN-EB3, is made by Regeneron Pharmaceuticals. The other, mAb114, was developed by the U.S. National Institutes of Health (NIH). Patients receiving these two drugs "had a greater chance of survival compared to those" receiving the other two drugs, the group found.
An experimental vaccine is also showing signs of effectiveness against the virus.
How were the drugs tested?
The research was designed to test the effectiveness of the drugs on as many as 725 people infected with the Ebola virus in North Kivu and Ituri provinces. An outbreak of Ebola in those parts of the DRC has killed more than 1,800 people since August 2018.
Ebola, a kind of hemorrhagic fever, has a very high rate of mortality. Dr. Michael Ryan of the World Health Organization said about 75 percent of those who become infected and receive no special care die.
But the recent study found that less than one-third of patients who were infected died when they took the two new drugs. Those patients who had low levels of the virus in their blood had even better results.
Among people who sought treatment early, the mortality rate was 6 percent for REGN-EB3 and the rate for mAb114 was 11 percent.
Dr. Ryan of the WHO said he hoped the results would persuade more patients to seek care as soon as symptoms appear. "Getting people into care more quickly is absolutely vital," he said.
However, treating the disease is made more difficult because the affected areas of the eastern DRC face ethnic conflict.
Jean-Jacques Muyembe, director general of the National Institute of Biomedical Research in DRC, helped lead the study. He said, "From now on, we will no longer say that Ebola is incurable."
I'm Mario Ritter Jr.
1.no longer 不再
They no longer had him as a friend.
2.ethnic conflict 种族冲突
How to eliminate ethnic prejudice and discriminate, and to reduce ethnic conflict?
3.compared to 与...比较
Our work can be compared to a battle.
4.special care 特殊护理
The patient needs special care during convalescence.
5.He said, "From now on, we will no longer say that Ebola is incurable."
From now on 从现在起
From now on you are free.
If it's lost, it's lost. Just be more careful from now on.
6.Dr. Ryan of the WHO said he hoped the results would persuade more patients to seek care as soon as symptoms appear.
as soon as 一...就
As soon as we found this out, we closed the ward.
He got married as soon as he graduated.
美国国立卫生研究院的安东尼·福奇称，早期试验结果是“一些非常好的消息 。”他说，这些新药“可能能够提高埃博拉患者的存活率 。”美国国立卫生研究院协助支持了这项研究 。
这一结果来自去年11月开始的对四种不同药物的研究 。但上周，一家独立监测组织建议提前结束这项研究 。该组织建议所有新增患者应该接受两种疗效最佳的药物中的其中一种 。
这些药物是通过阻断体内病毒发挥作用的抗体 。其中REGN-EB3药物是由新泽西再生元制药公司生产的 。另一种mAb114药物是由美国国立卫生研究院研制 。该组织发现，接受这两种药物治疗的患者比接受其他两类药物治疗的患者存活率更高 。
这项研究旨在测试这些药物对北基伍省和伊图里省725名埃博拉病毒感染者的疗效 。自2018年8月以来，刚果民主共和国的埃博拉疫情已造成1800多人死亡 。
埃博拉是一种出血热，死亡率很高 。世界卫生组织的迈克尔·瑞恩博士表示，大约75%的感染者没有接受特殊治疗而死亡 。
但这项最新研究发现，感染者服用这两种新药后的死亡率不到三分之一 。那些血液中病毒含量较低的患者疗效更佳 。
世卫组织的瑞恩博士表示，他希望这些研究结果可以说服更多患者在出现症状后立即寻求治疗 。他说：“让人们更早接受治疗绝对至关重要 。”